Patents Assigned to SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
-
Patent number: 11299469Abstract: Provided herein are methods of preparation of I by reacting i with acid where R1 and R2 are each independently a leaving group. Intermediates to make i are also claimed.Type: GrantFiled: November 29, 2017Date of Patent: April 12, 2022Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Jeevanandam Arumugasamy, Wei Li
-
Patent number: 11279694Abstract: Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and wherein at least one of R1, R2 and R3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.Type: GrantFiled: November 17, 2017Date of Patent: March 22, 2022Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Yusuke Sawayama, Wataru Hirose, Hitoshi Ban
-
Publication number: 20210228582Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.Type: ApplicationFiled: October 2, 2020Publication date: July 29, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
-
Publication number: 20210205304Abstract: Tartrate salts of the compound of structure (I), (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.Type: ApplicationFiled: November 9, 2020Publication date: July 8, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
-
Patent number: 11040038Abstract: Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).Type: GrantFiled: July 26, 2019Date of Patent: June 22, 2021Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.Inventors: Steven L. Warner, David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony, Paul Flynn, Yuji Fujiwara, Yuka Arikawa
-
Patent number: 11034710Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: GrantFiled: December 4, 2019Date of Patent: June 15, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
-
Patent number: 11013741Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.Type: GrantFiled: April 5, 2019Date of Patent: May 25, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
-
Publication number: 20210115006Abstract: The present invention relates to the composition and method of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.Type: ApplicationFiled: October 9, 2020Publication date: April 22, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
-
Publication number: 20210107883Abstract: Provided herein are methods of preparation of I by reacting i with acid where R1 and R2 are each independently a leaving group. Intermediates to make i are also claimed.Type: ApplicationFiled: November 29, 2017Publication date: April 15, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Jeevanandam Arumugasamy, Wei LI
-
Patent number: 10934309Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].Type: GrantFiled: December 27, 2018Date of Patent: March 2, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Hitoshi Ban, Seiji Kamioka, Shoukou Ri, Tomoyuki Furuta, Hiroyuki Kitano, Chiang Jia Li
-
Publication number: 20210052568Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.Type: ApplicationFiled: March 10, 2020Publication date: February 25, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Steven L. WARNER, David J. Bearss
-
Publication number: 20210024482Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.Type: ApplicationFiled: May 15, 2020Publication date: January 28, 2021Applicant: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
-
Patent number: 10888562Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.Type: GrantFiled: April 5, 2019Date of Patent: January 12, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
-
Patent number: 10875864Abstract: The present invention provides a compound having the following structure: Compositions and methods for using the same in the treatment of skin disorders and other Pim kinase-associated conditions are also disclosed.Type: GrantFiled: July 2, 2019Date of Patent: December 29, 2020Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
-
Patent number: 10851075Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: GrantFiled: October 16, 2018Date of Patent: December 1, 2020Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Patent number: 10835537Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.Type: GrantFiled: March 17, 2020Date of Patent: November 17, 2020Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
-
Patent number: 10766865Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: September 26, 2019Date of Patent: September 8, 2020Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
-
Patent number: 10752594Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: December 19, 2018Date of Patent: August 25, 2020Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss